Literature DB >> 18052408

Pediatric overactive bladder syndrome: pathophysiology and management.

Israel Franco1.   

Abstract

Detrusor overactivity, also known as the overactive bladder syndrome (OAB), urge syndrome, hyperactive bladder syndrome, persistent infantile bladder, and detrusor hypertonia, is the most common voiding dysfunction in children. Until recently, the concepts that had been used to dictate the management of this problem in children were based on the foundation that this was a primary bladder problem and or a delay in maturation in the nervous system of children. The expectation that children would outgrow their problems led many pediatric urologists and other practitioners to tell the parents of these children 'that they would not be wetting themselves on their wedding day.' However, it has become apparent from recent studies in adult patients with voiding dysfunctions that they had symptoms present as children. Recent findings of associations between lower urinary tract symptoms and sexual dysfunction and between voiding dysfunctions and neuropsychiatric problems have opened up a new frontier into the possible mechanisms of OAB in children that would explain these problems, link them together, and explain the continued problems that adult patients face. These findings point to OAB as a symptom of a more centrally located dysfunction that affects multiple systems. The objective of this review was to evaluate the neuroanatomy and neurophysiology of voiding and neuropharmacologic effects. We considered not only the available research and clinical data within the urologic field but also outside the field so that these data could be combined to generate a unified theory that could possibly explain many of the associated symptoms that are commonly found in pediatric OAB. Treatment modalities that are currently available for managing OAB were also explored. Currently available data indicate that pediatric OAB and many pediatric voiding dysfunctions may be part of a more generalized problem that affects multiple systems: notably bowels, bladder, sexual and ejaculatory function, control of blood pressure, and even mood and behavior. We explain the relationship that the bowel has with pediatric OAB and also the link that other neuropsychiatric problems have with OAB. This article describes which drug may be best suited to treat OAB in children and what treatment modalities are available when first-line drugs fail. In conclusion, the movement away from a vesicocentric way of thinking to a more corticocentric mode of thinking along with new imaging modalities that can examine the brain as it works will be of great value in determining future treatments of OAB. Medications generated from these evidence-based studies will hopefully treat the underlying disease process and not just the symptoms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052408     DOI: 10.2165/00148581-200709060-00005

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  62 in total

1.  Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.

Authors:  Viktoria Werkström; Anna Svensson; Karl-Erik Andersson; Petter Hedlund
Journal:  BJU Int       Date:  2006-04-18       Impact factor: 5.588

2.  Renal and bladder functional status at diagnosis as predictive factors for the outcome of primary vesicoureteral reflux in children.

Authors:  C K Yeung; B Sreedhar; J D Y Sihoe; F K Y Sit
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

3.  Increased prevalence of obesity in children with functional constipation evaluated in an academic medical center.

Authors:  Dinesh S Pashankar; Vera Loening-Baucke
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

4.  Transient urodynamic dysfunction of infancy: relationship to urinary tract infections and vesicoureteral reflux.

Authors:  M Chandra; H Maddix; M McVicar
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

Review 5.  Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?

Authors:  Steven M Finney; Karl-Erik Andersson; James I Gillespie; Laurence H Stewart
Journal:  BJU Int       Date:  2006-09       Impact factor: 5.588

6.  Urodynamic pattern in asymptomatic infants: siblings of children with vesicoureteral reflux.

Authors:  M Bachelard; U Sillén; S Hansson; G Hermansson; U Jodal; B Jacobsson
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

7.  A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders.

Authors:  Michael A Pezzone; Ruomei Liang; Matthew O Fraser
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

8.  Spontaneous resolution of high grade infantile vesicoureteral reflux.

Authors:  Sofia Sjöström; Ulla Sillén; Marc Bachelard; Sverker Hansson; Eira Stokland
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

Review 9.  Current and future pharmacological treatment for overactive bladder.

Authors:  Naoki Yoshimura; Michael B Chancellor
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

10.  Psychological problems in children with daytime wetting.

Authors:  Carol Joinson; Jon Heron; Alexander von Gontard
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

View more
  6 in total

1.  Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.

Authors:  Million Adane Tegenge; Helge Böhnel; Frank Gessler; Gerd Bicker
Journal:  Cell Mol Neurobiol       Date:  2012-02-29       Impact factor: 5.046

2.  Long-term prospective evaluation of an inpatient voiding reeducation program for lower urinary tract conditions in children.

Authors:  Tanja Golli; Anamarija Meglič; Rajko B Kenda
Journal:  Int Urol Nephrol       Date:  2013-02-05       Impact factor: 2.370

3.  Anticholinergic use in children: Persistence and patterns of therapy.

Authors:  Anne-Sophie Blais; Michelle Bergeron; Geneviève Nadeau; Sophie Ramsay; Stéphane Bolduc
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

Review 4.  Pharmacotherapy for Pediatric Neurogenic Bladder.

Authors:  Paweł Kroll
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

5.  Do uroflowmetry and post - void residual urine tests necessary in children with primary nocturnal enuresis?

Authors:  Shang-Jen Chang; Stephen Shei-Dei Yang
Journal:  Int Braz J Urol       Date:  2018 Jul-Aug       Impact factor: 1.541

6.  Evaluation of autonomic function in children and adolescents with overactive bladder.

Authors:  Rhaiana Gondim; Julia Gorjão; Ananda Nacif; Israel Franco; Ubirajara Barroso
Journal:  Int Braz J Urol       Date:  2021 Nov-Dec       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.